roivant sciences ltd - ROIV
ROIV
Close Chg Chg %
36.49 -0.54 -1.48%
Open Market
35.95
-0.54 (1.48%)
Volume: 5.02M
Last Updated:
Oct 26, 2026, 3:25 PM EDT
Company Overview: roivant sciences ltd - ROIV
ROIV Key Data
| Open $36.66 | Day Range 35.66 - 36.91 |
| 52 Week Range 17.89 - 42.50 | Market Cap $27.05B |
| Shares Outstanding 722.32M | Public Float 524.29M |
| Beta 1.10 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$0.38 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 6.45M |
ROIV Performance
| 1 Week | 0.00% | ||
| 1 Month | 1.93% | ||
| 3 Months | 4.23% | ||
| 1 Year | 100.27% | ||
| 5 Years | 359.57% |
ROIV Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
15
Full Ratings ➔
About roivant sciences ltd - ROIV
Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.
ROIV At a Glance
Roivant Sciences Ltd.
50 Broadway
London, Greater London SW1H 0BD
| Phone | 44-207-400-3347 | Revenue | 8.26M | |
| Industry | Pharmaceuticals: Major | Net Income | -299,771,000.00 | |
| Sector | Health Technology | Employees | 721 | |
| Fiscal Year-end | 03 / 2027 | |||
| View SEC Filings |
ROIV Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 2,326.882 |
| Price to Book Ratio | 4.407 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -12.489 |
| Enterprise Value to Sales | 1,912.45 |
| Total Debt to Enterprise Value | 0.007 |
ROIV Efficiency
| Revenue/Employee | 11,456.311 |
| Income Per Employee | -415,771.151 |
| Receivables Turnover | 0.01 |
| Total Asset Turnover | 0.001 |
ROIV Liquidity
| Current Ratio | 18.373 |
| Quick Ratio | 18.373 |
| Cash Ratio | 15.274 |
ROIV Profitability
| Gross Margin | 43.91 |
| Operating Margin | -15,353.547 |
| Pretax Margin | -3,203.123 |
| Net Margin | -3,629.189 |
| Return on Assets | -5.37 |
| Return on Equity | -6.506 |
| Return on Total Capital | -6.468 |
| Return on Invested Capital | -6.377 |
ROIV Capital Structure
| Total Debt to Total Equity | 2.373 |
| Total Debt to Total Capital | 2.318 |
| Total Debt to Total Assets | 1.876 |
| Long-Term Debt to Equity | 2.127 |
| Long-Term Debt to Total Capital | 2.078 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Roivant Sciences Ltd - ROIV
Collapse All in section
| All values USD millions. | 2023 | 2024 | 2025 | 2026 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 61.28M | 124.80M | 29.05M | 8.26M | |
Sales Growth
| +10.84% | +103.65% | -76.72% | -71.57% | |
Cost of Goods Sold (COGS) incl D&A
| 32.08M | 27.96M | 8.24M | 4.63M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 26.42M | 22.04M | 7.33M | 3.35M | |
Depreciation
| 18.95M | 12.40M | 7.33M | 3.35M | |
Amortization of Intangibles
| - | - | 7.47M | 9.63M | - |
COGS Growth
| +257.82% | -12.84% | -70.52% | -43.79% | |
Gross Income
| 29.20M | 96.83M | 20.81M | 3.63M | |
Gross Income Growth
| -36.96% | +231.64% | -78.51% | -82.57% | |
Gross Profit Margin
| +47.65% | +77.59% | +71.63% | +43.91% |
| 2023 | 2024 | 2025 | 2026 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 1.11B | 1.18B | 1.13B | 1.27B | |
Research & Development
| 525.22M | 501.74M | 550.41M | 681.81M | |
Other SG&A
| 581.55M | 675.04M | 584.08M | 590.02M | |
SGA Growth
| -12.03% | +6.33% | -3.59% | +12.11% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 196.56M | 153.37M | (70.94M) | (810.48M) | |
EBIT after Unusual Expense
| (1.27B) | (1.23B) | (1.04B) | (457.73M) | |
Non Operating Income/Expense
| 77.27M | 5.52B | 361.15M | 193.15M | |
Non-Operating Interest Income
| 32.18M | 146.43M | 258.38M | 178.11M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | 27.97M | 34.78M | - |
Interest Expense Growth
| - | +297.22% | +24.35% | -100.00% | |
Gross Interest Expense
| - | - | 27.97M | 34.78M | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (1.22B) | 4.25B | (681.59M) | (264.58M) | |
Pretax Income Growth
| -32.59% | +447.27% | -116.02% | +61.18% | |
Pretax Margin
| -1,998.75% | +3,408.33% | -2,346.02% | -3,203.12% | |
Income Tax
| 5.19M | 22.22M | 48.17M | 133.33M | |
Income Tax - Current - Domestic
| 5.31M | 22.53M | 48.17M | 53.47M | |
Income Tax - Current - Foreign
| - | (122.00K) | (310.00K) | 79.86M | |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (1.23B) | 4.23B | (729.76M) | (397.91M) | |
Minority Interest Expense
| (106.43M) | (117.72M) | (184.75M) | (98.14M) | |
Net Income
| (1.12B) | 4.35B | (545.01M) | (299.77M) | |
Net Income Growth
| -32.93% | +487.06% | -112.53% | +45.00% | |
Net Margin Growth
| -1,833.54% | +3,484.86% | -1,875.92% | -3,629.19% | |
Extraordinaries & Discontinued Operations
| - | - | 114.56M | 373.03M | - |
Discontinued Operations
| - | - | 114.56M | 373.03M | - |
Net Income After Extraordinaries
| (1.01B) | 4.35B | (171.98M) | (299.77M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (1.01B) | 4.35B | (171.98M) | (299.77M) | |
EPS (Basic)
| -1.4156 | 5.5524 | -0.2371 | -0.432 | |
EPS (Basic) Growth
| -12.17% | +492.23% | -104.27% | -82.20% | |
Basic Shares Outstanding
| 712.79M | 783.25M | 725.40M | 693.86M | |
EPS (Diluted)
| -1.4156 | 5.2331 | -0.2371 | -0.432 | |
EPS (Diluted) Growth
| -12.17% | +469.67% | -104.53% | -82.20% | |
Diluted Shares Outstanding
| 712.79M | 831.05M | 725.40M | 693.86M | |
EBITDA
| (1.05B) | (1.06B) | (1.11B) | (1.26B) | |
EBITDA Growth
| - | -0.64% | -4.58% | -14.33% | |
EBITDA Margin
| -1,715.32% | -847.72% | -3,808.04% | -15,313.01% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 48.909 | |
| Number of Ratings | 15 | Current Quarters Estimate | -0.365 | |
| FY Report Date | 12 / 2026 | Current Year's Estimate | -1.378 | |
| Last Quarter’s Earnings | -0.37 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -0.54 | Next Fiscal Year Estimate | -1.309 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 11 | 11 | 12 | 12 |
| Mean Estimate | -0.37 | -0.35 | -1.38 | -1.31 |
| High Estimates | -0.17 | -0.16 | -0.72 | -0.53 |
| Low Estimate | -0.53 | -0.50 | -1.96 | -2.10 |
| Coefficient of Variance | -29.95 | -31.09 | -26.38 | -38.09 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 11 | 11 | 10 |
| OVERWEIGHT | 2 | 3 | 2 |
| HOLD | 2 | 1 | 1 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Roivant Sciences Ltd - ROIV
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Roivant Sciences Ltd - ROIV
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Oct 21, 2026 | Mayukh Sukhatme President & CIO; Director | 18,563,884 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $33.53 per share | 622,447,030.52 |
| Oct 21, 2026 | Matthew Gline CEO; Director | 16,549,136 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $33.53 per share | 554,892,530.08 |
| Oct 6, 2026 | Melissa B. Epperly Director | 32,704 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $4.46 per share | 145,859.84 |
| Oct 6, 2026 | Melissa B. Epperly Director | 15,854 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $36.08 per share | 572,012.32 |
| Oct 6, 2026 | Melissa B. Epperly Director | 14,954 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $36.57 per share | 546,867.78 |
| Oct 6, 2026 | Melissa B. Epperly Director | 151,416 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Oct 5, 2026 | Frank M. Torti President and Vant Chair | 13,495,893 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $36.57 per share | 493,544,807.01 |
| Oct 5, 2026 | Eric Venker President & Immunovant CEO | 1,799,154 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $3.85 per share | 6,926,742.90 |
| Oct 5, 2026 | Eric Venker President & Immunovant CEO | 1,599,154 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $36.62 per share | 58,561,019.48 |
| Oct 5, 2026 | Eric Venker President & Immunovant CEO | 3,644,834 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Sep 15, 2026 | James C. Momtazee Director | 106,905 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $40.94 per share | 4,376,690.70 |
| Sep 15, 2026 | Meghan M. Fitzgerald Director | 41,220 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $40.94 per share | 1,687,546.80 |
| Sep 15, 2026 | Daniel Allen Gold Director | 8,960,761 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $40.94 per share | 366,853,555.34 |
| Sep 15, 2026 | Ilan Oren Director | 118,626 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $40.94 per share | 4,856,548.44 |